Página principal > Artículos > Resultados de la búsqueda: Majem, Margarita

Artículos

  Consejos para la búsqueda
Búsqueda avanzada
Buscar colecciones:
Ordenar por: Mostrar resultados: Formato de visualización:
Artículos Encontrados 41 registros  anterior11 - 20siguientefinal  ir al registro: La búsqueda tardó 0.00 segundos. 
11.
9 p, 902.3 KB Assessment of the psychosocial and economic impact according to sex in non-small cell lung cancer patients : an exploratory longitudinal study / Viñolas, Nuria (Hospital Clínic i Provincial de Barcelona) ; Garcia-Campelo, Rosario (Complejo Hospitalario Universitario de A Coruña) ; Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Isla, Dolores (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ; Gonzalez-Larriba, José Luis (Hospital Clínico San Carlos (Madrid)) ; Coves, Juan (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ; De-Castro, Javier (Hospital Universitario La Paz (Madrid)) ; Domine, Manuel (Hospital Universitario Fundación Jiménez Díaz) ; Lianes, Piar (Hospital de Mataró. Consorci Sanitari del Maresme) ; Artal, Ángel (Hospital Universitario Miguel Servet (Saragossa)) ; Remon, Jordi (CIOCC Barcelona - HM Delfos) ; Felip, Enriqueta (Hospital Universitari Vall d'Hebron) ; Garrido, Pilar (Hospital Universitario Ramón y Cajal (Madrid)) ; Universitat Autònoma de Barcelona
Little is known about the impact of sex on lung cancer patients from the psychological, economic and social perspectives. This study was designed to explore the psychosocial and economic impact according to sex of metastatic non-small cell lung cancer (mNSCLC) in patients and caregivers. [...]
2020 - 10.1186/s40359-020-00489-z
BMC Psychology, Vol. 8 Núm. 1 (december 2020) , p. 123  
Registro completo - Creative Commons
12.
14 p, 425.7 KB Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC : Primary and Correlative Biomarker Analyses / Owonikoko, Taofeek K. (Winship Cancer Institute of Emory University) ; Niu, Huifeng (Millennium Pharmaceuticals. Inc.) ; Nackaerts, Kristiaan (KU Leuven. Universitaire Ziekenhuizen) ; Csoszi, Tibor (Hetenyi G Korhaz) ; Ostoros, Gyula (Orszagos Koranyi TBC es Pulmonologiai Intezet) ; Mark, Zsuzsanna (Tudogyogyintezet Torokbalint) ; Baik, Christina (University of Washington Seattle Cancer Care Alliance) ; Joy, Anil Abraham (University of Alberta. Cross Cancer Institute) ; Chouaid, Christos (CHI de Créteil) ; Jaime, Jesus Corral (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; Kolek, Vitezslav (Fakultni Nemocnice Olomouc) ; Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Roubec, Jaromir (Fakultni Nemocnice Ostrava) ; Santos, Edgardo S. (Lynn Cancer Institute/Boca Raton Regional Hospital) ; Chiang, Anne C. (Yale University School of Medicine) ; Speranza, Giovanna (Université de Sherbrooke) ; Belani, Chandra P. (Penn State Cancer Institute) ; Chiappori, Alberto (H. Lee Moffitt Cancer Center) ; Patel, Manish R. (Florida Cancer Specialists/Sarah Cannon Research Institute) ; Czebe, Krisztina (Tudogyogyintezet Torokbalint) ; Byers, Lauren (Tudogyogyintezet Torokbalint) ; Bahamon, Brittany (Millennium Pharmaceuticals. Inc.) ; Li, Cong (Millennium Pharmaceuticals. Inc.) ; Sheldon-Waniga, Emily (Millennium Pharmaceuticals. Inc.) ; Kong, Eric F. (University of Texas M. D. Anderson Cancer Center) ; Williams, Miguel (Millennium Pharmaceuticals. Inc.) ; Badola, Sunita (Millennium Pharmaceuticals. Inc.) ; Shin, Hyunjin (Millennium Pharmaceuticals. Inc.) ; Bedford, Lisa (Millennium Pharmaceuticals. Inc.) ; Ecsedy, Jeffrey A. (Millennium Pharmaceuticals. Inc.) ; Bryant, Matthew (University of Texas M. D. Anderson Cancer Center) ; Jones, Sian (University of Texas M. D. Anderson Cancer Center) ; Simmons, John (University of Texas M. D. Anderson Cancer Center) ; Leonard, E. Jane (Millennium Pharmaceuticals. Inc.) ; Ullmann, Claudio Dansky (Millennium Pharmaceuticals. Inc.) ; Spigel, David R. (Personal Genome Diagnostics) ; Universitat Autònoma de Barcelona
We assessed the Aurora A kinase inhibitor, alisertib, plus paclitaxel (henceforth referred to as alisertib/paclitaxel) as second-line treatment for SCLC. In this double-blind study, patients with relapsed or refractory SCLC were stratified by relapse type (sensitive versus resistant or refractory) and brain metastases and randomized 1:1 to alisertib/paclitaxel or placebo plus paclitaxel (henceforth referred to as placebo/paclitaxel) in 28-day cycles. [...]
2020 - 10.1016/j.jtho.2019.10.013
Journal of Thoracic Oncology, Vol. 15 Núm. 2 (february 2020) , p. 274-287  
Registro completo - Creative Commons
13.
16 p, 1.6 MB Multidisciplinary consensus statement on the clinical management of patients with stage III non-small cell lung cancer / Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Hernández-Hernández, J. (Complejo Asistencial de Ávila) ; Hernando-Trancho, F. (Hospital Clínico San Carlos (Madrid)) ; Rodríguez de Dios, Nuria (Hospital del Mar (Barcelona, Catalunya)) ; Sotoca, A. (Hospital Ruber Internacional) ; Trujillo-Reyes, J.C. (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ; Vollmer, I. (Hospital Clínic i Provincial de Barcelona) ; Delgado-Bolton, R. (Hospital San Pedro de Alcántara) ; Provencio, M. (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ; Universitat Autònoma de Barcelona
Stage III non-small cell lung cancer (NSCLC) is a very heterogeneous disease that encompasses patients with resected, potentially resectable and unresectable tumours. To improve the prognostic capacity of the TNM classification, it has been agreed to divide stage III into sub-stages IIIA, IIIB and IIIC that have very different 5-year survival rates (36, 26 and 13%, respectively). [...]
2020 - 10.1007/s12094-019-02134-7
Clinical & Translational Oncology, Vol. 22 Núm. 1 (january 2020) , p. 21-36  
Registro completo - Creative Commons
14.
10 p, 1.1 MB SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019) / Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; García-Martínez, E. (Hospital General Universitario Morales Meseguer (Múrcia)) ; Martinez, M. (Hospital del Mar (Barcelona, Catalunya)) ; Muñoz Couselo, Eva (Vall d'Hebron Institut d'Oncologia) ; Rodriguez-Abreu, D. (C.H.U. Insular-Materno Infantil de Gran Canaria) ; Alvarez, R. (Hospital Virgen de la Salud (Toledo)) ; Arance, Ana (Hospital Clínic i Provincial de Barcelona) ; Berrocal, A. (Hospital General Universitario de Valencia) ; de la Cruz Merino, Luis (Universidad de Sevilla) ; Lopez-Martin, Jose A (Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12)) ; Universitat Autònoma de Barcelona
The use of immune checkpoint inhibitors has emerged as an effective treatment option for patients with several tumor types. By increasing the activity of the immune system, they can induce inflammatory side effects, which are often termed immune-related adverse events. [...]
2020 - 10.1007/s12094-019-02273-x
Clinical & Translational Oncology, Vol. 22 Núm. 2 (january 2020) , p. 213-222  
Registro completo - Creative Commons
15.
6 p, 380.2 KB Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer : final results of a randomised phase 2 clinical trial / Gridelli, C. (S.G. Moscati Hospital) ; Ciuleanu, Tudor Eliade (Institutui. Oncologic I. Chircuta) ; Domine, M. (Fundacion Jimenez Diaz) ; Szczesna, A. (Mazowieckie Centrum) ; Bover, I. (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ; Cobo, M. (Instituto de Investigaciones Biomédicas (IBIMA)) ; Kentepozidis, N. (251 General Airforce Hospital) ; Zarogoulidis, K. (Papanikolaou General Hospital) ; Kalofonos, C. (University Hospital of Patras) ; Kazarnowisz, A. (Oddzial Onkologiiz Pododdziatem) ; Korozan, M. (Hospicjum Dutkiewicza SAC) ; de las Peñas, R (Hospital Provincial de Castellon) ; Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Chella, A. (A.O.U. di Pisa Hospital) ; Griesinger, F. (Pius Hospital) ; Bournakis, E. (University Hospital "Aretaieion") ; Sadjadian, P. (Johannes Wesling Klinikum) ; Kotsakis, A. (University General Hospital of Larissa) ; Chinet, T. (Hopital Ambroise Paré) ; Syrigos, K.N. (General Hospital of Thoracic Diseases "Sotiria") ; Correale, P. (University Hospital of Siena) ; Gallou, C. (Vaxon-Biotech) ; Jamet, J.M. (Vaxon-Biotech) ; Vetsika, E.K. (University General Hospital of Heraklion) ; Kosmatopoulos, K. (Vaxon-Biotech) ; Georgoulias, V. (University General Hospital of Heraklion) ; Universitat Autònoma de Barcelona
The cancer vaccine Vx-001, which targets the universal tumour antigen TElomerase Reverse Transcriptase (TERT), can mount specific Vx-001/TERT CD8 + cytotoxic T cells; this immune response is associated with improved overall survival (OS) in patients with advanced/metastatic non-small cell lung cancer (NSCLC). [...]
2020 - 10.1038/s41416-020-0785-y
British Journal of Cancer, Vol. 122 Núm. 10 (december 2020) , p. 1461-1466  
Registro completo - Creative Commons
16.
11 p, 421.8 KB Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial / Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Goldman, Jonathan W. (David Geffen School of Medicine. University of California Los Angeles) ; John, Thomas (Department of Medical Oncology. Austin Health) ; Grohe, Christian (Klinik fur € Pneumologie-Evangelische Lungenklinik Berlin Buch) ; Laktionov, Konstantin (N.N. Blokhin National Medical Research Center of Oncology (Rússia)) ; Kim, Sang-We (Department of Oncology. Asan Medical Center) ; Kato, Terufumi (Depart-ment of Thoracic Oncology. Kanagawa Cancer Center) ; Vu, Huu Vinh (Department of Thoracic Surgery. Choray Hospital) ; Lu, Shun (Lung Cancer Center. Shanghai Chest Hospital. Shanghai Jiao Tong University) ; Li, Shanqing (Department of Thoracic Surgery. Peking Union Medical College Hospital. Chinese Academy of Medical Sciences) ; Lee, Kye Young (Pre-cision Medicine Lung Cancer Center. Konkuk University Medical Center) ; Akewanlop, Charuwan (Division of Medical Oncology. Faculty of Medicine. Siriraj Hospital) ; Yu, Chong-Jen (Department of Internal Medicine. National Taiwan University Hospital Hsinchu Branch. National Taiwan University College of Medicine) ; De Marinis, Filippo (Thoracic Oncology Division. European Institute of Oncology (IEO). IRCCS) ; Bonanno, Laura (Medical Oncology 2. Istituto Oncologico Veneto (IOV). IRCCS) ; Domine, Manuel (Hospital Universitario Fundacion Jimenez Díaz. Servicio de Oncología) ; Shepherd, Frances A. (Department of Medical Oncology and Hematology. University Health Network. Princess Margaret Cancer Center. the University of Toronto) ; Atagi, Shinji (Department of Thoracic Oncology. National Hospital Organization Kinki-Chuo Chest Medical Center) ; Zeng, Lingmin (Late Oncology Statistics. AstraZeneca) ; Kulkarni, Dakshayini (Late Oncology R&D. AstraZeneca) ; Medic, Nenad (AstraZeneca Oncology Business Unit. Academy House) ; Tsuboi, Masahiro (Department of Thoracic Surgery and Oncology. National Cancer Center Hospital East) ; Herbst, Roy S. (Medical Oncology. Yale School of Medicine. Yale Cancer Center) ; Wu, Yi-Long (Guangdong Lung Cancer Institute)
Purpose: In the phase III ADAURA trial, adjuvant treatment with osimertinib versus placebo, with/without prior adjuvant chemotherapy, resulted in a statistically significant and clinically meaningful disease-free survival benefit in completely resected stage IB-IIIA EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC). [...]
2022 - 10.1158/1078-0432.CCR-21-3530
Clinical Cancer Research, Vol. 28 Núm. 11 (january 2022) , p. 2286-2296  
Registro completo - Creative Commons
17.
12 p, 719.9 KB SEOM clinical guideline emesis (2021) / Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; de las Peñas, Ramon (Hospital Provincial Castelló. Servei d'Oncologia Mèdica) ; Virizuela, Juan Antonio (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ; Cabezón-Gutiérrez, Luís (Hospital Universitario de Torrejón. Servicio de Oncología Médica) ; Cruz, Patricia (Hospital Universitario La Paz (Madrid)) ; Lopez-Castro, Rafael (Hospital Clínico Universitario de Valladolid) ; Méndez, Miriam (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ; Mondéjar, Rebeca (Hospital Universitario de La Princesa. Servicio de Oncología Médica) ; Muñoz, María del Mar (Hospital "Virgen de la Luz" (Conca). Servicio de Oncología Médica) ; Escobar, Yolanda (Hospital General Universitario "Gregorio Marañón". Servicio de Oncología Médica)
Among the side effects of anticancer treatment, chemotherapy-induced nausea and vomiting (CINV) is one of the most feared given its high prevalence, affecting up to 40% of patients. It can impair patient's quality of life and provoke low adherence to cancer treatment or chemotherapy dose reductions that can comprise treatment efficacy. [...]
2022 - 10.1007/s12094-022-02802-1
Clinical & Translational Oncology, Vol. 24 Núm. 4 (april 2022) , p. 712-723  
Registro completo - Creative Commons
18.
17 p, 534.5 KB COAST : An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination with Oleclumab or Monalizumab in Patients with Unresectable, Stage III Non-Small-Cell Lung Cancer / Herbst, Roy S. (Yale Cancer Center. Smilow Cancer Hospital) ; Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Barlesi, Fabrice (Gustave Roussy) ; Carcereny, Enric (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ; Chu, Quincy (Cross Cancer Institute) ; Monnet, Isabelle (Centre Hospitalier Intercommunal de Créteil) ; Sánchez Hernández, Alfredo (Consorci Hospitalari Provincial de Castelló) ; Dakhil, Shaker (Cancer Center of Kansas) ; Camidge, D (University of Colorado Anschutz Medical Campus) ; Winzer, Leanne (AstraZeneca) ; Soo-Hoo, Yee (AstraZeneca) ; Cooper, Zachary A. (AstraZeneca) ; Kumar, Rakesh (AstraZeneca) ; Bothos, John (AstraZeneca) ; Aggarwal, Charu (Abramson Cancer Center. University of Pennsylvania) ; Martinez-Marti, Alex (Vall d'Hebron Institut d'Oncologia)
PURPOSEDurvalumab significantly improves overall survival for patients with unresectable stage III non-small-cell lung cancer and no progression after concurrent chemoradiotherapy (cCRT). Building upon that standard of care, COAST is a phase II study of durvalumab alone or combined with the anti-CD73 monoclonal antibody oleclumab or anti-NKG2A monoclonal antibody monalizumab as consolidation therapy in this setting. [...]
2022 - 10.1200/JCO.22.00227
Journal of Clinical Oncology, Vol. 3 (january 2022) , p. JCO.22.00227  
Registro completo - Creative Commons
19.
11 p, 3.4 MB PIVOT-12 : a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence / Eggermont, Alexander M. (Princess Máxima Center for Pediatric Oncology & University Medical Center Utrecht) ; Ascierto, Paolo A. (Istituto Nazionale Tumori IRCCS Fondazione G Pascale) ; Khushalani, Nikhil I. (H Lee Moffitt Cancer Center & Research Institute) ; Schadendorf, Dirk (West German Cancer Center at the University Hospital Essen) ; Boland, Genevieve (Massachusetts General Hospital (Boston)) ; Weber, Jeffrey (Perlmutter Cancer Center at NYU Langone Health) ; Lewis, Karl D. (University of Colorado Cancer Center) ; Johnson, Daniel (Ochsner Medical Center) ; Rivalland, Gareth (University of Auckland & Auckland City Hospital) ; Khattak, Adnan (Hollywood Private Hospital. Edith Cowan University) ; Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Gogas, Helen (National & Kapodistrian University of Athens) ; Long, Georgina V. (Melanoma Institute Australia. University of Sydney. Royal North Shore & Mater Hospitals) ; Currie, Sue L. (Nektar Therapeutics, San Francisco, CA 94158, USA) ; Chien, David (Nektar Therapeutics, San Francisco, CA 94158, USA) ; Tagliaferri, Mary A. (Nektar Therapeutics, San Francisco, CA 94158, USA) ; Carlino, Matteo S. (Westmead & Blacktown Hospitals & Melanoma Institute Australia. University of Sydney) ; Diab, Adi (University of Texas MD Anderson Cancer Center)
Bempegaldesleukin (BEMPEG: NKTR-214) is an immunostimulatory IL-2 cytokine prodrug engineered to deliver a controlled, sustained and preferential IL-2 pathway signal. Nivolumab (NIVO), a PD-1 inhibitor, has been shown to prolong survival in patients with advanced melanoma and recurrence-free survival in the adjuvant setting. [...]
2022 - 10.2217/fon-2021-1286
Future oncology (London, England), Vol. 18 Núm. 8 (january 2022) , p. 903-913  
Registro completo - Creative Commons
20.
7 p, 657.6 KB Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations / Cortellini, Alessio (Imperial College London) ; Ricciuti, Biagio (Lowe Center for Thoracic Oncology. Dana Farber Cancer Institute) ; Vaz, Victor R. (Lowe Center for Thoracic Oncology. Dana Farber Cancer Institute) ; Soldato, Davide (Cancer Medicine Department. Gustave Roussy) ; Alessi, Joao V. (Lowe Center for Thoracic Oncology. Dana Farber Cancer Institute) ; Dall'olio, Filippo G. (Cancer Medicine Department. Gustave Roussy) ; Banna, Giuseppe L. (Candiolo Cancer Institute. FPO-IRCCS) ; Muthuramalingam, Sethupathi (Oncology Department. United Lincolnshire Hospital NHS Trust) ; Chan, Samuel (Oncology Department. Queen Alexandra University Hospital. Portsmouth Hospitals NHS Trust) ; Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Piedra, Aida (Institut d'Investigació Biomèdica Sant Pau) ; Lamberti, Giuseppe (Department of Experimental Diagnostic and Specialty Medicine. S. Orsola-Malpighi University Hospital. Alma Mater Studiorum University of Bologna) ; Andrini, Elisa (Department of Experimental Diagnostic and Specialty Medicine. S. Orsola-Malpighi University Hospital. Alma Mater Studiorum University of Bologna) ; Addeo, Alfredo (Medical Oncology. University Hospital of Geneva) ; Friedlaender, Alex (Medical Oncology. University Hospital of Geneva) ; Facchinetti, Francesco (Université Paris-Saclay) ; Gorriá, Teresa (Hospital Clínic i Provincial de Barcelona) ; Mezquita, Laura (Hospital Clínic i Provincial de Barcelona) ; Hoton, Delphine (Department of Pathology. Cliniques Universitaires Saint-Luc) ; Valerie, Lacroix (Department of Cardiovascular and Thoracic Surgery. IREC. Cliniques Universitaires Saint-Luc) ; Nana, Frank Aboubakar (Institut de Recherche Expérimentale et Clinique (IREC). Pôle de Pneumologie. ORL et Dermatologie (PNEU). Université Catholique de Louvain (UCLouvain)) ; Artingstall, James (Bristol Haematology and Oncology Centre) ; Comins, Charles (Bristol Haematology and Oncology Centre) ; Di Maio, Massimo (Department of Oncology. University of Turin and Mauriziano Hospital) ; Caglio, Andrea (Department of Oncology. University of Turin and Mauriziano Hospital) ; Cave, Judith (Department of Medical Oncology. University Hospital Southampton NHS Foundation Trust) ; McKenzie, Hayley (Department of Medical Oncology. University Hospital Southampton NHS Foundation Trust) ; Newsom-Davis, Thomas (Department of Oncology. National Centre for HIV Malignancies. Chelsea and Westminster Hospital) ; Evans, Joanne S. (Imperial College London) ; Tiseo, Marcello (Medical Oncology Unit. University Hospital of Parma) ; D'Alessio, Antonio (Department of Biomedical Sciences. Humanitas University) ; Fulgenzi, Claudia A.M. (Department of Medical Oncology. University Campus Bio-Medico) ; Besse, Benjamin (School of Medicine. University Paris-Saclay) ; Awad, Mark M. (Lowe Center for Thoracic Oncology. Dana Farber Cancer Institute) ; Pinato, David J. (Division of Oncology. Department of Translational Medicine. University of Piemonte Orientale)
Introduction It has been recognized that increasing body mass index (BMI) is associated with improved outcome from immune checkpoint inhibitors (ICIs) in patients with various malignancies including non-small cell lung cancer (NSCLC). [...]
2022 - 10.1136/jitc-2021-004374
Journal for immunotherapy of cancer, Vol. 10 Núm. 2 (February 2022) , p. e004374  
Registro completo - Creative Commons

Artículos : Encontrados 41 registros   anterior11 - 20siguientefinal  ir al registro:
Vea también: autores con nombres similares
6 Majem, M.
1 Majem, Margarita,
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.
Depósito Digital de Documentos de la UAB :: Buscar :: Enviar :: Personalizar :: Ayuda
Powered by Invenio v1.1.6
Mantenido por ddd.bib@uab.cat  :: Metadatos sujetos a:
Colaboramos